Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00730158 · ClinicalTrials.gov registry record · Phase 2
A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer
A Phase 2 study of Colorectal Neoplasms, sponsored by Edward Chu, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 2
- Study locations
NCT00730158 is a Phase 2 study of Colorectal Neoplasms that has completed, run by Edward Chu, MD. The registered enrollment target is 33 participants, below the 576-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00730158, a Phase 2 study of Colorectal Neoplasms, has completed, sponsored by Edward Chu, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 2
- Study locations
Study Summary
The proposed plan will investigate the mechanism and efficacy of Chinese herbal medicine as an adjunct to chemotherapy in treatment of patients with metastatic colorectal cancer. Our rationale for the therapeutic use of KD018 is its potential activity in reducing chemotherapy-induced toxicity, especially diarrhea.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Irinotecan
- DRUG KD018
Study Locations (2)
Connecticut
- Yale University Comprehensive Cancer Center - New Haven
Pennsylvania
- Hillman CancerCenters - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2008-12 |
| Est. Completion | 2018-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00730158
The ClinicalTrials.gov registry entry for NCT00730158 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 576-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (94% lower). The listed sponsor is Edward Chu, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00730158 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00730158 about?
NCT00730158 is a clinical study titled "A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer". The proposed plan will investigate the mechanism and efficacy of Chinese herbal medicine as an adjunct to chemotherapy in treatment of patients with metastatic colorectal cancer. Our rationale for the therapeutic use of KD018 is its potential activity in reducing chemotherapy-induced toxicity, espec...
What is the current status of trial NCT00730158?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2008-12. Estimated completion is 2018-06.
What conditions does trial NCT00730158 study?
This clinical trial studies the following conditions: Colorectal Neoplasms.
What interventions are being tested in trial NCT00730158?
The interventions under investigation include: Placebo (DRUG), Irinotecan (DRUG), KD018 (DRUG).
Who is sponsoring clinical trial NCT00730158?
This trial is sponsored by Edward Chu, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00730158 being conducted?
This trial has 2 study locations across Connecticut, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
RECRUITING · Phase 2
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
ACTIVE NOT RECRUITING · Phase 2
-
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
COMPLETED · Phase 2
-
A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.